文献速递骨软组织肉瘤与黑色素瘤

PD-1靶向治疗晚期骨肉瘤:PEMBROSARC研究结果

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.
PubMed 文献 · Eur J Cancer · 2019-08-21

PEMBROSARC是一项开放标签、多中心2期研究,评估帕博利珠单抗联合节拍环磷酰胺治疗晚期骨肉瘤。17例患者入组,50例可评估疗效,客观缓解率6.7%,6个月无进展率13.3%(95%CI 1.7-40.5)。PD-1抑制在骨肉瘤中活性有限。

要点

  • 帕博利珠单抗联合节拍环磷酰胺在晚期骨肉瘤中客观缓解率仅6.7%。
  • 6个月无进展率为13.3%(95%CI 1.7-40.5),未达预设有效阈值。
  • PD-L1表达率低,仅14例可检样本中2例阳性,唯一缓解者PD-L1阴性。

核心结论

  • PD-1抑制在骨肉瘤中活性有限,需进一步研究PD-1抑制剂联合微环境调节药物。

研究设计与样本

  • 开放标签、多中心2期研究,评估帕博利珠单抗联合节拍环磷酰胺治疗晚期骨肉瘤。
  • 双主要终点为6个月无进展率和客观缓解率(RECIST 1.1版)。

主要发现

  • 4例患者肿瘤缩小,1例(6.7%)达部分缓解。
  • 6个月无进展率为13.3%(95%CI 1.7-40.5)。
  • 最常见不良事件为I或II级恶心、贫血、厌食和乏力。
  • PD-L1表达率低,14例可检肿瘤样本中仅2例阳性。
  • 唯一部分缓解患者为PD-L1阴性肿瘤。

关键数值与推荐

  • 客观缓解率20%和/或6个月无进展率60%被确定为有意义疗效的合理目标。
  • 帕博利珠单抗200 mg静脉注射每3周一次,环磷酰胺50 mg每日两次,用一周停一周。

临床怎么用

  • PD-1单药联合节拍环磷酰胺不作为晚期骨肉瘤的优先推荐方案。
  • 临床决策时应考虑PD-L1表达状态及微环境调节策略的联合探索。

局限性

  • 样本量小(17例入组),疗效评估存在不确定性。
  • PD-L1表达数据有限,仅14例有可用肿瘤材料。
  • 未报告随机对照或长期生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. PATIENTS AND METHODS: This was an open-label, multicentre, phase 2 study of pembrolizumab in combination with metronomic cyclophosphamide in patients with advanced osteosarcomas. All patients received 50 mg b.i.d. of cyclophosphamide one week on and one week off and 200 mg of intravenous pembrolizumab (every 3 weeks). There was a dual primary end-point, encompassing both the non-progression and objective responses at 6 months per Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1. An objective response rate of 20% and/or a 6-month non-progression rate of 60% were determined as reasonable objectives for treatment with meaningful effect. Correlative studies of immune biomarkers were planned from the patients' tumour samples. RESULTS: Between October 13 2015 and July 3 2017, 17 patients were included. Fifty were assessable for the efficacy end-point. Four patients experienced tumour shrinkage, resulting in a partial response (PR) in one patient (6.7%). The 6-month non-progression rate was 13.3% (95% confidence interval [CI]: 1.7-40.5). The most frequent adverse events were grade I or II nausea, anaemia, anorexia and fatigue. programmed death-ligand 1 (PD-L1) expression rate was low, observed in only 2 cases of 14 with available tumour material. The only patient who experienced PR had a PD-L1-negative tumour. CONCLUSION: Programmed cell death 1 (PD-1) inhibition has limited activity in osteosarcomas. Further studies investigating PD-1 inhibitor in combination with agents modulating the microenvironment are warranted. TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov, number NCT02406781.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Cesne A, Marec-Berard P, Blay JY, et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019. PMID: 31442817. doi:10.1016/j.ejca.2019.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。